Antengene to Present Results From Four Cutting Edge Preclinical Studies at AACR 2025 with Focuses Including AnTenGagerTM TCEs and Synthetic Lethality
SHANGHAI and HONG KONG, March 26, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing...